Dr Cauwenbergh succeeds Joos Horsten, who recently passed away. Dr Cauwenbergh has been assisting Rhei Pharmaceuticals since August 1, 2008 in providing the necessary leadership to continue the company’s development.
Prior to joining Rhei Pharmaceuticals, Dr Cauwenbergh founded phases123, a company focused on identifying high potential health care technology platforms and emerging health care companies.
The company has also received approval from the Chinese health authorities to launch its final clinical study for Asacard, a controlled release formulation of aspirin. With this approval in place, Rhei Pharmaceuticals has a low-risk pipeline of novel western medicines lined up for the Chinese market, with multiple product launches expected over the next few years.
Dr Cauwenbergh said: “As a result of Joos’s leadership and foresight, Rhei Pharmaceuticals is uniquely positioned to accelerate the availability of already approved western medicines in the Chinese market and I am fortunate to be working with the world-class team that Joos had assembled in order to pursue its growth strategy.”